🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Ph Positive ALL

Olverembatinib Combined With Venetoclax and Azacitidine in Blast Phase Ph Chromosome-positive CML NCT06757855Phase 1, Phase 21 site📍 Tianjin Institute of Hematology & Blood Diseases Hospital, China · Tests: Olverembatinib, Venetoclax, Azacitidine A Study on the Tolerability, Safety and Effectiveness of Asciminib in Patients With Philadelphia Chromosome-positive Chronic Myeloid Leukemia in the Chronic Phase in Germany NCT07549516n/a69 sites📍 Baden-Baden📍 Heidenheim📍 Schwäbisch Hall Novartis Pharmaceuticals CD19 CAR-T vs DLI for Post-HSCT MRD in Ph- ALL: A RCT NCT07441291Phase 31 site📍 Beijing Peking University People's Hospital · Tests: CAR-T, DLI Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL NCT04260022Phase 19 sites📍 Birmingham📍 Duarte📍 Atlanta Ascentage Pharma Group Inc. · Tests: Ascentage Pharma HQP1351 bioavailable inhibitor, Blinatumomab Efficacy and Safety of TKI Combined With Chemotherapy and Sequential CAR-T Cells in ND Adult Patients With Ph+ ALL NCT06481228NA1 site📍 Tianjin Institute of Hematology & Blood Diseases Hospital, China · Tests: CAR-T cells, Venetoclax, Olverembatinib EWALL-PH OBSERVARTORY 2022 NCT07684131n/a23 sites📍 Amiens📍 Angers📍 Bayonne Versailles Hospital A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL) NCT06124157Phase 2161 sites📍 Birmingham📍 Phoenix📍 Tucson National Cancer Institute (NCI) · Tests: Biospecimen Collection, Blinatumomab, Bone Marrow Biopsy, Calaspargase Pegol, Cyclophosphamide Phase I/II Study of the Combination of Blinatumomab and Asciminib in Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia NCT06308588Phase 1, Phase 22 sites📍 The Bronx📍 Houston M.D. Anderson Cancer Center · Tests: Blinatumomab, Asciminib Comparing the Efficacy of Nab-PH+Pyrrolitinib and TCbHP in the Neoadjuvant Treatment of HER2 Positive BC NCT05918328Phase 21 site📍 Zhengzhou Henan Cancer Hospital · Tests: Albumin paclitaxel+trastuzumab+pyrrolitinib, Docetaxel+Carboplatin+trastuzumab+Parstuzumab Venetoclax Combined With Olverembatinib and Predinisone in Treating Ph+ B-ALL NCT06754267Phase 21 site📍 Hangzhou First Affiliated Hospital of Zhejiang University · Tests: Venetoclax, Olverembatinib, Predinisone ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML NCT03595917Phase 14 sites📍 Chicago📍 Boston📍 Boston Marlise Luskin, MD · Tests: ABL001, Dasatinib, Prednisone, Blinatumomab Asciminib as Maintenance Treatment After Cellular Therapies for Adults With Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia NCT07040982Phase 11 site📍 Duarte City of Hope Medical Center · Tests: Asciminib, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Echocardiography Test Randomized Trial in Adult de Novo Ph Positive ALL With Chemotherapy, Imatinib or Ponatinib, Blinatumomab and SCT NCT06061094Phase 285 sites📍 Aachen📍 Aschaffenburg📍 Augsburg Goethe University · Tests: Imatinib, Ponatinib, Blinatumomab, Indication for stem cell transplantation Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia NCT04925479Phase 1, Phase 239 sites📍 Indianapolis📍 Boston📍 Jackson Novartis Pharmaceuticals · Tests: Asciminib Pediatric formulation group, Asciminib Adult formulation group Ph 2 Elacestrant in ER Positive Uterine Sarcomas NCT07467772Phase 21 site📍 Boston Dana-Farber Cancer Institute · Tests: Elacestrant Markers to Evaluate the Efficacy of PH-based Regimen as a Neoadjuvant Therapy for Operable HER2 Positive Breast Cancer NCT04281641NA1 site📍 Shanghai Fudan University · Tests: TCHP Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL) NCT07387926Phase 1, Phase 24 sites📍 Sydney📍 Ramat Gan📍 Seoul Novartis Pharmaceuticals · Tests: Asciminib Adult formulation, Asciminib Pediatric formulation, Dexamethasone, Vincristine, Blinatumomab Long-term Progression of Patients Treated and Monitored for Relapsed or Refractory Ph+ ALL NCT07433400n/a1 site📍 Pierre-Bénite Group for Research in Adult Acute Lymphoblastic Leukemia A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1) NCT06051409Phase 390 sites📍 Birmingham📍 Duarte📍 Los Angeles Ascentage Pharma Group Inc. · Tests: Olverembatinib, Investigator's choice of TKI Ponatinib Hydrochloride as Second Line Therapy in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib Mesylate, Dasatinib, or Nilotinib NCT01746836Phase 21 site📍 Houston M.D. Anderson Cancer Center · Tests: Laboratory Biomarker Analysis, Ponatinib Hydrochloride, Quality-of-Life Assessment Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia NCT03263572Phase 21 site📍 Houston M.D. Anderson Cancer Center · Tests: Blinatumomab, Cytarabine, Methotrexate, Ponatinib A Study of LP-118 In Combination With Ponatinib, Dexamethasone And Blinatumomab For Adults With Newly-Diagnosed, BCR::ABL1-Positive Acute Lymphoblastic Leukemia (ALL) NCT07614022Phase 12 sites📍 Charlotte📍 Winston-Salem Wake Forest University Health Sciences · Tests: LP-118 A Single-arm, Open-label Study of Olverembatinib, CD3/CD19 Bispecific T-cell Engager, and Chidamide in Patients With Newly Diagnosed Ph+ALL NCT06220487Phase 21 site📍 Guangzhou Nanfang Hospital, Southern Medical University · Tests: Prednisone, Olverembatinib, Blinatumomab, Chidamide Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia NCT03739814Phase 2285 sites📍 Birmingham📍 Anchorage📍 Anchorage National Cancer Institute (NCI) · Tests: Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration, Bone Marrow Biopsy, Inotuzumab Ozogamicin A Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failure or Intolerance to Previous TKIs NCT03459534Phase 318 sites📍 Barnaul📍 Kirov📍 Moscow Il-Yang Pharm. Co., Ltd. · Tests: Radotinib HCl A Phase I Study of Decitabine, Lisaftoclax, and Olverembatinib in Patients With Advanced Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Myeloid Leukemia NCT06401603Phase 11 site📍 Houston M.D. Anderson Cancer Center · Tests: Decitabine, Listaftoclax, Olverembatinib A Ph II Study of the TheraBionic P1 Device in Subjects With Hormone Positive Breast Cancer NCT07227831NA8 sites📍 Bay City📍 Clarkston📍 Detroit Barbara Ann Karmanos Cancer Institute · Tests: TheraBionic P1 Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/Lymphoma NCT07224100Phase 21 site📍 Seattle University of Washington · Tests: Cyclophosphamide, Doxorubicin, Etoposide, Filgrastim, Pegfilgrastim A Multicenter Study of CAR-T Cells in Primary Ph+All NCT07252336Phase 21 site📍 Hangzhou Zhejiang University · Tests: CD19 CAR-T cells Newly-diagnosed Pediatric Ph-positive B-ALL Protocol NCT07152041Phase 324 sites📍 Hefei📍 Chongqing📍 Fuzhou Institute of Hematology & Blood Diseases Hospital, China · Tests: olverembatinib
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy